TY - JOUR
T1 - Natriuretic peptides in cardiovascular diseases
T2 - Current use and perspectives
AU - Volpe, Massimo
AU - Rubattu, Speranza
AU - Burnett, John
N1 - Funding Information:
This work was supported by a grant (Ricerca Corrente) from the Italian Ministry of Health to M.V. and S.R.; by the 5‰ grant to M.V. and S.R.; by PRIN 2009 to S.R.; by InGenious Hypercare European project to M.V.
PY - 2014/2
Y1 - 2014/2
N2 - The natriuretic peptides (NPs) family, including atrial, B-type, and C-type NPs, is a group of hormones possessing relevant haemodynamic and anti-remodelling actions in the cardiovascular (CV) system. Due to their diuretic, natriuretic, vasorelaxant, anti-proliferative, and anti-hypertrophic effects, they are involved in the pathogenic mechanisms leading to major CV diseases, such as heart failure (HF), coronary artery disease, hypertension and left ventricular hypertrophy, and cerebrovascular accidents. Blood levels of NPs have established predictive value in the diagnosis of HF, as well as for its prognostic stratification. In addition, they provide useful clinical information in hypertension and in both stable and unstable coronary artery disease. Structural abnormalities of atrial natriuretic peptide gene (NPPA), as well as genetically induced changes in circulating levels of NPs, have a pathogenic causal link with CV diseases and represent emerging markers of CV risk. Novel NP-based therapeutic strategies are currently under advanced clinical development, as they are expected to contribute to the future management of hypertension and HF.The present review provides a current appraisal of NPs' clinical implications and a critical perspective of the potential therapeutic impact of pharmacological manipulation of this class of CV hormones.
AB - The natriuretic peptides (NPs) family, including atrial, B-type, and C-type NPs, is a group of hormones possessing relevant haemodynamic and anti-remodelling actions in the cardiovascular (CV) system. Due to their diuretic, natriuretic, vasorelaxant, anti-proliferative, and anti-hypertrophic effects, they are involved in the pathogenic mechanisms leading to major CV diseases, such as heart failure (HF), coronary artery disease, hypertension and left ventricular hypertrophy, and cerebrovascular accidents. Blood levels of NPs have established predictive value in the diagnosis of HF, as well as for its prognostic stratification. In addition, they provide useful clinical information in hypertension and in both stable and unstable coronary artery disease. Structural abnormalities of atrial natriuretic peptide gene (NPPA), as well as genetically induced changes in circulating levels of NPs, have a pathogenic causal link with CV diseases and represent emerging markers of CV risk. Novel NP-based therapeutic strategies are currently under advanced clinical development, as they are expected to contribute to the future management of hypertension and HF.The present review provides a current appraisal of NPs' clinical implications and a critical perspective of the potential therapeutic impact of pharmacological manipulation of this class of CV hormones.
KW - ARNi
KW - Cardiovascular diseases
KW - Genetics
KW - NEP inhibitors
KW - Natriuretic peptides
KW - Natriuretic peptides analogues
UR - http://www.scopus.com/inward/record.url?scp=84894256771&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894256771&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/eht466
DO - 10.1093/eurheartj/eht466
M3 - Review article
C2 - 24227810
AN - SCOPUS:84894256771
SN - 0195-668X
VL - 35
SP - 419-425c
JO - European heart journal
JF - European heart journal
IS - 7
ER -